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Xenotransplantation: Using Animals to Save Human Lives
For the thousands of patients in need of organ transplants, they know all too well that the
supply of viable organs in the United States is critically low. Due to this shortage, medical
institutions must decide who is most deserving of the organs that are available by filtering
through patients’ histories and conditions. In short, they must decide who is most worth saving.
What if there was a way to solve this shortage? Thanks to advances in medical science, there
may be a solution. Research has been conducted for a process that is being called
xenotransplantation, which involves using cells and tissues from one organism and transplanting
them to another. In theory, tissues or whole organs from other animals could be donated to
humans in need of lifesaving organ transplants. However, there are many controversies
surrounding this concept. Is it ethical to genetically modify animals and harvest their organs for
our own benefit? Could doing so create another pandemic caused by a virus transmitted from
humans to animals? Would living with another animal’s organ inside a person alter their
perspective of what makes them human? This project hopes to explore the complex ethical
dilemmas behind xenotransplantation to spark a discussion about medical research and its
impacts.
What is Xenotransplantation?
Through examining the makeup of the term, one could gather that the process of
xenotransplantation involves the placement or transfer of some outside substance into another
unrelated substance as the prefix of the word defines the foreign nature of the material being
transplanted. More specifically, the United States Food and Drug Administration (FDA) defines
the term as:
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Any procedure that involves the transplantation, implantation or infusion into a human
recipient of either (a) live cells, tissues, or organs from a nonhuman animal source, or (b)
human body fluids, cells, tissues or organs that have had ex vivo contact with live
nonhuman animal cells, tissues or organs (USFDA, 2021).
The ex vivo detail simply means that any human matter must come into contact with
nonhuman animal matter outside of the human body before being transplanted into the human
recipient. Initially, scientists believed that the ideal animal sources for this process were
nonhuman primate (NHPs), which included animals like monkeys, baboons, and chimpanzees.
This was a natural assumption due to evolutionary theory that shows humans and NHPs in close
relation. However, researchers found that “despite their close phylogenic relationship with
humans, NHPs were found to not be suitable for a number of reasons, including ethical concerns,
costs, difficulties in generating genetic modifications, and biosafety” (Carrier et al., 2022).
Surprisingly, the transition was then made for pigs to be used as the ideal animal specimen for
xenotransplantation. Pigs are suitable for a multitude of reasons:
Pigs are physiologically similar to humans, reach sexual maturity within several months
and have large litter sizes, have a lower risk of zoonosis than NHPs and they can be
reared under specific pathogen free (SPF) housing conditions further reducing risk of
infections (Fischer and Schnieke, 2022).
Additionally, pigs are much less challenging to raise as compared to NHPs and
techniques on rearing established through the farming industry can aid experimenters in
cultivating mass populations of pigs in the most cost effective way possible.
Modification of Organs and the Challenges Posed
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Before pig cells can be implanted into humans, the cells must be modified for
compatibility with the human body. The target of this modification is the very code of life, the
cell’s DNA. Changing the DNA or genome is done by a Clustered Regularly Interspaced Short
Palindromic Repeat, more commonly known as CRISPR, and a CRISPR associated (Cas-9)
protein (Asmamaw and Zawdie, 2021). Together, these two form the CRISPR/Cas-9 genomeediting system. CRISPRs are small sections of the DNA where there is repetition within the
code, and these sections of code can be cleaved by the Cas-9 protein to allow for inactivation or
introduction of new genes (Asmamaw and Zawdie, 2021). Inactivation of existing genes or
introduction of new ones modifies the pig organs to become more viable in a human host.
Once the cells have been modified, there are additional steps that must be taken before
they are ready for human transplantation. To test how the human immune system will react to the
genetically modified organ (GMO), the organ is placed in an “in vitro assay,” which will run
human blood serum through the organ (Fischer and Schnieke, 2022). Researchers carefully
examine the in vitro assay to look for indicators of inflammation, cell apoptosis, or blood clot
formation, all of which indicate that the human blood is mounting an immune attack against the
modified pig organ. Once it is proven that the organ can thrive in the blood serum, the organ is
then transplanted into a nonhuman primate for further testing. This validation step is called “in
vivo” (Fischer and Schnieke, 2022). As previously discussed, NHPs are the closest animal
relatives to humans, therefore, they make the ideal candidate for experimental transplantation
before the modified pig organs can be approved for clinical use in humans. If all goes well, the
organ will eventually be transplanted into a human recipient who will be closely monitored to
assess the new organ’s functioning and overall transplant success.
The Consequences of Improper Genome-Editing
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Despite scientists’ valiant efforts to prevent an immune flare-up or organ rejection,
sometimes the modified pig organs are not compatible with the human body. When the human
immune system mounts an attack against the transplanted organ, the organ can face one of three
types of rejection: “hyperacute rejection, acute humoral rejection, and acute cellular rejection”
(Carrier et al., 2022). Hyperacute rejection can occur “within minutes to few hours of transplant
due to preformed antibodies in recipient’s blood” (Carrier et al., 2022). These preformed
antibodies in the human immune system will recognize a specific antigen on the surface of the
pig cells that should have been repressed if genome-editing was successful. After recognition,
the antibodies will group around the antigens, disrupting blood flow through the transplanted
organ and impede proper functioning.
Should the organ survive the 24-hour mark, the risk of acute humoral rejection (AHR) is
now a possibility. AHR is similar to hyperacute rejection in that it also involves a humoral
response from human antibodies; however, AHR additionally recruits other immune cells to
attack the foreign organ (Carrier et al., 2022). Lastly, the third type of organ rejection, acute
cellular rejection, involves “NK [natural killer] cells, macrophages, neutrophils, T-cells and BCells” that attempt to destroy the transplanted organ (Carrier et al., 2022). Any one of these three
types of rejection pose a major challenge for the success rate of genetically-modified organ
transplants. It is crucial that scientists correctly edit the DNA of the pig cells to be supported by
the human immune system, and it is equally important that the human recipient undergoes
immune suppression in preparation to receive a foreign organ. According to Carrier et al. (2022),
“a successful immunosuppression protocol should involve the combination of agents that can
increase the length of transplant and have the least side effects on the recipient.” The side effects
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of rejection caused by a reaction with an improperly modified organ can have life-threatening
effects on the patient.
Real-life, Human Cases of Xenotransplantation
Kidney Transplants from NHPs
In the 1960s, several smaller-scale experiments and procedures with xenotransplantation
had been performed decades prior and proved mildly successful. Inspired by these cases, Keith
Reemtsma of Tulane University hoped to prove that NHP kidneys could serve as suitable
replacements for human kidneys. The NHP source he selected was the chimpanzee, harvesting
kidneys from these animals and using them for thirteen transplant procedures (Cooper et al.,
2015). As previously stated, NHPs were still believed to be the ideal non-human organ sources at
the time as researchers had not yet discovered the potential of porcine organs. All but one of
Reemtsma’s transplants failed within four to eight weeks after the procedures, with the lucky
patient surviving for nine months with a kidney from a non-human source (Cooper et al., 2015).
Though the longest transplant case was ultimately deemed a failure due to the patient’s eventual
death, Reemtsma’s experiments contributed greatly to the progression of xenotransplantation.
Baby Faye
One of the most well-known cases of cardiac xenotransplantation is the 1983 case of
Baby Faye. Baby Faye was an infant girl that was born with a congenital heart defect that
required immediate medical attention. Complicated procedures on infants are much more
challenging to perform compared to fully-developed adults, however, the difficulty of the
procedure was increased even more as “it was almost impossible to obtain human organs from
infants” for use in transplants (Cooper et al., 2015). Desperate to save Baby Faye’s life, Leonard
Bailey instead replaced her diseased heart with the heart of a baboon. As noble as the surgeon’s
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intentions were, the procedure was for naught because “the graft underwent acute rejection and
the patient died 20 days later” (Cooper et al., 2015). Understandably, the case of Baby Faye did
not do much to promote the possibilities of xenotransplantation in the future of medicine.
Instead, Cooper et al. (2015) argues that Bailey’s efforts brought the issue of organ scarcity to
the public’s attention, especially for infants in need of transplants.
Recent Cases: 2021 and 2022
The field of xenotransplantation has made major strides in the past two years. Three
recent cases have shown the life-saving potential of non-human organs and the outcomes of these
cases emphasize the need for more research and funding for this growing field of medicine.
Compared to the aforementioned procedures, two of the more recent cases differ in the fact that
the patients receiving the modified organs were brain-dead. In September of 2021 at New York
University, a modified porcine kidney was transplanted into the femoral blood vessels of a braindead patient at the permission of the patient’s family (Carrier et al., 2022). For many hours
following the operation, the organ was “closely monitored and noted to make urine, clear
creatinine, and show no overt signs of rejection” (Carrier et al., 2022). Using the results from this
procedure, NYU performed another kidney transplant on November 22, 2021 in another braindead patient (DeVries, 2021). Similar to the September case, the kidney was assessed for
functioning and rejection status and the results from the previous procedure were upheld in this
second trial. Dr. Montgomery, the physician who led both of these operations, expressed, “There
is much more work to do before we begin living human trials, but our preliminary findings give
us hope” (DeVries, 2021). With more research, it is the hope of Dr. Montgomery and many other
medical professionals, that xenotransplantation could remedy the national organ shortage.
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The third most recent case marked a historic point in the timeline of xenotransplantation,
as the transplantation of a porcine heart into a living human recipient was the first of its kind.
The surgery took place on January 7, 2022, at the University of Maryland Medical Center
(UMMC). The patient was David Bennet, a 57-year-old man who was in end-stage heart failure
with no option for a traditional heart transplant. Bennet was rapidly declining in health before the
surgery, “bedridden for eight weeks with a life-threatening arrhythmia and was connected to a
heart-lung bypass machine;” he was able to be weaned from the machine and undergo
rehabilitation after the transplant was performed (Kotz and Seiler, 2022). Bennet survived for
two more months before finally succumbing to heart failure. As of June 2022, there were still
ongoing investigations into the cause behind the failure of the porcine heart. Possible factors
under consideration are an intravenous drug that contains antibodies that may have reacted
poorly with the modified organ, and traces of a pig virus that could have caused an infection
within Bennet’s body (Kotz and Seiler, 2022). Many of the professionals involved in this
transplantation were optimistic that Bennet’s case brought xenotransplantation one step closer to
clinical reality for patients in dire need of organ transplants.
Ethical Implications of Xenotransplantation
Xenotransplantation could be an exciting new solution to the organ shortage problem our
nation currently faces. At the end of February 2022, the United States government estimated that
there were around 116,690 patients that were awaiting organ transplant surgery, with the supply
of readily available organs being nowhere near enough to satisfy this demand (Fischer &
Schnieke, 2022). Once scientists perfect the process of xenotransplantation, biomedical facilities
could produce enough genetically modified organs to close this gap. However, there are many
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ethical concerns that are standing in the way of this breakthrough science advancing to medical
reality.
The first major critique against xenotransplantation regards informed consent, a crucial
element in any medical procedure. Informed consent involves a medical professional relaying
information to a patient concerning the procedure they will undergo, the benefits and risks of
said procedure, and if there are any alternatives to the treatment that has been proposed. The
information must be phrased to not pressure the patient into a specific decision or present any
biases a medical professional may hold. There are three standards that informed consent is
typically judged by:
(1) Subjective standard: What would this patient need to know and understand to make an
informed decision? (2) Reasonable patient standard: What would the average patient
need to know to be an informed participant in the decision? (3) Reasonable physician
standard: What would a typical physician say about this procedure? (Shah et al., 2022)
There has been argument about the amount and adequacy of information that can be
given to patients regarding xenotransplantation. Much is still unknown about animal organs
being used in human bodies, therefore, some argue that patients cannot truly consent to a
procedure as complex as this. Informed consent, according to Cozzi et al. (2021), can be
complicated due to the “remaining uncertainties regarding the unintended effects of
xenotransplantation” (p. 2014). Since physicians cannot fully understand how this kind of
transplantation will affect a patient, how can we be sure that patients are receiving adequate
information to make the decision to consent to this procedure? This issue continues to be pushed
back and forth in major ethical committees as xenotransplantation cannot progress until informed
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consent is improved, but informed consent cannot be improved until more research on
xenotransplantation is done.
Introducing animal organs into human bodies raises the public health concern of
outbreaks of zoonotic infections. The COVID-19 virus, theorized to have been passed from an
animal to humans, is still a major public health concern after the pandemic saw its height in
2020. Though it has not yet been undeniably proven that COVID-19 is a zoonotic disease, the
heightened public awareness of potential diseases that animals pass on to humans has been
apparent. In relation to the issue of informed consent, there is not much information surrounding
the probability of a human recipient contracting an infection from a modified animal organ.
However, the risk does exist as research has discovered “porcine endogenous retroviruses can
infect human cells in vitro” (Shapiro, 2022, p. 211). Regardless of the likelihood of a patient
contracting a porcine retrovirus, the existence of this risk is enough to challenge the benefits that
xenotransplantation proposes in fear of creating another global pandemic.
If the problem of zoonotic disease was eliminated and people with modified animal
organs were able to survive and did not pose a health risk to others, how would their changed
biology impact the definition of human? Though this question may seem exaggerative, this
argument has surfaced in critiques of xenotransplantation. It is thought that implanting animal
tissue and DNA into a human violates the biology and genome of the recipient, turning them into
a sort of chimera. The National Cancer Institute (n.d.) defines a chimera as “tissue that contains
cells with different genes than the rest of the person, organ, or tissue.” Ultimately, what makes
someone human is a subjective definition. With enough information, the patient will be able to
decide for themselves if they can accept receiving an organ of non-human nature.
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Many critiques of xenotransplantation focus on the effects on the patient, however, there
are other concerns regarding the usage and treatment of animals for this science. Pigs that are
being used for organ harvesting must be kept in laboratory settings and are subjected to
experimentation and testing to become ideal candidates for organ transplant. To ensure ethical
treatment of animals, there have been many legislative efforts passed protecting animal rights
such as the Animal Welfare Act (AWA), passed in 1966. The main points of the act are as
follows:
Protects all warm-blooded animals except rats, mice, and birds bred for research. This
includes zoos, circuses, research labs, hospitals, businesses, federal agencies, dealers,
breeders, etc. Each research institution that uses a covered species must have an IACUC
review all animal experiment protocols. The USDA licenses research facilities and
conducts annual, unannounced inspections. Violations are punished with fines, ceaseand-desist orders, and license suspension or revocation. (National Research Council,
2004, p. 33)
The IACUC, stands for Institutional Animal Care and Use Committee, is a committee
created by the AWA to approve and oversee the use of animals in scientific research. This
committee ensures that animals are being treated ethically during experimentation and that their
use serves a purpose or obviously contributes to the advancement of medicine. However valiant
their efforts are, some argue that these committees and regulations do not adequately protect
animals. PETA, People for the Ethical Treatment of Animals, is an animal rights organization
that vehemently argues against the use of animals for scientific research. They claim, “the
majority of animal experiments do not contribute to improving human health, and the value of
the role that animal experimentation plays in most medical advances is questionable” (PETA,
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2022). It is difficult to argue against the frightening experience that animals face when used for
experimentation, being raised in environments completely unnatural to them. However,
xenotransplantation cannot be ruled out completely for the usage of animals when one considers
the good that could come from this science. These animals, more specifically pigs, could be used
to create organs for life-saving transplants and lessen the severity of the organ shortage crisis.
Conclusion
Xenotransplantation is far from becoming a commonplace treatment for organ failure,
however, progressing research and recent documented cases of the procedure are promising.
Though using non-human materials for medical purposes is not a novel concept, medical
professionals have never been so close to seeing xenotransplantation become a reality as they
were this year with a transplanted pig heart surviving two months in a human recipient. This
breakthrough was met with many harsh criticisms including the inadequacy of informed consent
in this kind of procedure, the risk-reward balance being disturbed with greater risks than benefits,
and the exploitation of animals for scientific gain. The ethical and moral complexities
surrounding the issue of xenotransplantation are likely to increase as research on the topic
progresses, however, resolution of these ethical arguments may be possible with further
discussion of the benefits and detriments of this experimental procedure.
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